Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.45 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023177 | 0.83 | SIGMAR1 (0.77) | SIGMAR1 | |
| SCHEMBL3123686 | 0.83 | HDAC6 (0.56) | SIGMAR1EPHX1MAPTCXCR4PKM | |
| SCHEMBL23023029 | 0.83 | SIGMAR1 (0.77) | SIGMAR1 | |
| SCHEMBL10425868 | 0.81 | SIGMAR1 (0.73) | SIGMAR1MAPT | |
| SCHEMBL23022866 | 0.77 | SIGMAR1 (0.69) | SIGMAR1MAPT | |
| SCHEMBL29444840 | 0.75 | MEN1 (0.56) | CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL1347800 | 0.74 | CXCR4 (0.47) | SIGMAR1CXCR4CXCL12ALDH1A1 | |
| SCHEMBL13928873 | 0.74 | CXCR4 (0.47) | SIGMAR1CXCR4CXCL12 | |
| SCHEMBL31547204 | 0.73 | SIGMAR1 (0.88) | SIGMAR1CXCR4CXCL12 | |
| SCHEMBL22495345 | 0.73 | SIGMAR1 (0.63) | SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1147469-C | Novel urea derivatives bearing nitrogenous aromatic heterocycles | ������ҩ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| US-6420398-B2 | FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| CN-1318051-A | Novel urea derivative having aromatic nitrogen-containing heterocycle | SANTEN PHARMACEUTICAL CO LTD (JP) | 2001-10-17 | — | — | CN | disclosed |
| EP-1103543-A1 | NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | TNF, UACA, HRH4 | SIGMAR1 339/4885EPHX1 1295/4885MAPT 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.